Protalix BioTherapeutics, Inc.
AMEX: PLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dror Bashan
- Employees
- 213
- Headquarters
- Hackensack, United States
- IPO year
- 1998
- Market cap
- $178.9M
- Website
- https://www.protalix.com
Loading PLX…
Loading profile data…Frequently asked questions about PLX
What does Protalix BioTherapeutics, Inc. (PLX) do?
Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins. The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients...
Where does PLX trade?
Protalix BioTherapeutics, Inc. (PLX) trades on the New York Stock Exchange American.
What sector is PLX in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Protalix BioTherapeutics, Inc.?
Dror Bashan is the chief executive officer of Protalix BioTherapeutics, Inc. (PLX).
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. is headquartered in United States.
Does PLX pay a dividend?
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PLX go public?
Protalix BioTherapeutics, Inc. (PLX) completed its initial public offering in 1998.